The burgeoning popularity of semaglutide , initially for diabetes , is creating significant attention within the British Isles, prompting a notable shift in hormone trends. Obtaining these treatments remains a complex challenge , with NHS provision currently limited and specialist practices offering therapy at a premium . Concerns are being raised